As reviewed by Nguyen-Khac, the double-hit CLL (bearing TP53 aberration + MYC gain) might have an inferior outcome even within the delTP53 group, but these results from a limited retrospective study have yet to be confirmed in larger cohorts of patients (23). Here, TP53 is linked to B-cell chronic lymphocytic leukemia.